Anaphylactic Shock News and Research

RSS

Anaphylactic shock or anaphylaxis is a severe and sometimes life-threatening immune system reaction to an antigen that a person has been previously exposed to. The reaction may include itchy skin, edema, collapsed blood vessels, fainting, difficulty in breathing, and death.

Specific commercial red algae could help combat food allergies

Seaweed has long been a staple food in many Asian countries and has recently caught on as a snack food in America as a healthful alternative to chips. The edible algae that fall in the category of seaweed are low-calorie and packed with nutrients

2 Jun 2016

Breakthrough technique removes potentially harmful additives from common injectable drugs

Bring the drugs, hold the suds. That summarizes a promising new drug-making technique designed to reduce serious allergic reactions and other side effects from anti-cancer medicine, testosterone and other drugs that are administered with a needle.

20 May 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

Hypersexual disorder can be linked to hyperactive stress systems

New research from Karolinska Institutet in Sweden shows that hypersexual disorder - known popularly as sex addiction - can be linked to hyperactive stress systems. In a stress regulation test using the cortisone drug dexamethasone, men with hypersexual disorder showed higher levels of stress hormones than controls, a finding that the researchers hope will contribute to improved therapy for this patient group.

3 Nov 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

New cell type appears to drive life-threatening food allergies

Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.

22 Sep 2015

New research reveals why some kids can have severe allergic reaction hours later

Parents of kids with severe allergies know how scary a severe allergic reaction (anaphylaxis) is. New research offers clues as to why some kids can have a second, related reaction hours later - and what to do about it.

8 Jul 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

EpiPen (epinephrine) emergency kits now available at Montreal Bell Centre for treating severe allergies

Pfizer Canada Inc., the distributor of EpiPen, and the Montreal Bell Centre are pleased to announce that EpiPen (epinephrine) emergency kits are now available at the Bell Centre, home of the Montreal Canadiens hockey team. The new partnership strives to offer a safeguarded environment for visitors at risk of serious allergic reactions during hockey games, concerts and other entertainment events.

1 Apr 2015

UConn chemists develop more advanced peanut allergy test

Current peanut allergy tests are not very reliable when it comes to diagnosing the severity of an individual's allergic reaction, which can range from hives to life-threatening anaphylactic shock.

27 Feb 2015

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

New ingredient in gluten-free products can cause allergic reaction

A popular new ingredient in gluten-free products could be causing an allergic reaction, according to a Kansas State University food safety specialist.

26 Aug 2014

Wake Forest Baptist Physician offers tips to prevent bites and rashes in summer

When summer rolls around, nothing beats soaking up the rays, hiking in a forest or playing Frisbee with the family … until a mosquito, bee or poisonous plant ruins the fun.

28 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

Research team designs new type of flour that could control food allergies without side effects

These days, more and more people seem to have food allergies, which can sometimes have life-threatening consequences. In ACS' Journal of Agricultural and Food Chemistry, scientists report the development of a new type of flour that someday could be used in food-based therapies to help people better tolerate their allergy triggers, including peanuts.

15 May 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Asthma drug accelerates desensitization in patients with food allergies to several foods

An asthma drug accelerates the process of desensitizing patients with food allergies to several foods at the same time, a new study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford shows.

3 Mar 2014

Lone star tick bites are likely the cause of severe red meat allergies

Lone star tick bites are likely the cause of thousands of cases of severe red meat allergies that are plaguing patients in Southeastern states including Tennessee, North Carolina and Virginia and spreading up the Eastern Seaboard along with the deer population.

21 Feb 2014

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

Most people have heard of severe allergies, or anaphylaxis, to food, insect stings, drugs and other common substances, but sometimes no cause at all can be found for a person’s reaction – a condition called Idiopathic anaphylaxis.